Proof of concept STEP-52 trial shows treatment efficacy and stability of PTSD symptoms when moving from unregulated drug to APEX-52 GMP drug product. VANCOUVER, BC, March 29, 2023 /CNW/ – Apex Labs Ltd. (APEX or the Company), a pharmaceutical company optimizing the standard of mental health care with clinically proven psilocybin treatments, is pleased to announce the completion of the first-ever…


Previous articleBetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
Next articleNuminus to Host Q2 2023 Results Conference Call on April 13, 2023